# Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

> **NCT04003974** · PHASE2 · COMPLETED · sponsor: **Fulcrum Therapeutics** · enrollment: 80 (actual)

## Conditions studied

- Facioscapulohumeral Muscular Dystrophy (FSHD)

## Interventions

- **DRUG:** Losmapimod oral tablet
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04003974
- **Lead sponsor:** Fulcrum Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-09
- **Primary completion:** 2021-01-28
- **Final completion:** 2021-01-28
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003974, "Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04003974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*